Greater Paris University Hospitals, AP-HP & IntegraGen Agree to a Research Partnership to Develop a Common Platform for High-...
June 29 2016 - 1:37PM
Business Wire
The Greater Paris University Hospitals, AP-HP and the molecular
genomics company IntegraGen announced today the signature of an
agreement to develop a high-throughput sequencing platform (exome
and whole genome) to be utilized for research projects and clinical
research initiatives. This three-year research partnership aligns
with a major objective of the AP-HP’s 2015-2019 Strategic Plan
related to providing clinicians and patients access to newer health
innovations and technological advancements. The agreement was
approved by the Executive Board of the AP-HP on June 28, 2016.
Through the framework of this agreement, researchers,
clinicians, and biologists of the AP-HP, one of the largest patient
referral centers in Europe, will benefit from IntegraGen’s
experience and expertise in large scale, industrial high throughput
sequencing projects and its ability to deliver high quality data.
This represents a major breakthrough for researchers at AP-HP since
some were obliged to send DNA abroad to be sequenced prior to this
agreement. This agreement represents an essential first step in the
development of a formalized national personalized medicine
initiative as a part of the French Plan for Genomic Medicine
2025.
The current initiative will enable sequencing data collected
from biological samples to be transformed into genomic information
and molecular diagnostic tools. The common high-throughput
sequencing platform developed as a result of this agreement will be
utilized for research projects in the fields of cancer, rare
diseases, microbiology, and potentially psychiatry. Researchers
utilizing this platform will have access to an integrated solution
encompassing all stages of genomic analysis, from the collection of
the biological sample to the delivery of sequencing results.
"Sequencing is a complex process requiring perfect control of
all stages of the analysis of biological samples. The bioinformatic
analysis of large amounts of sequencing data is also a major
challenge,” stated Bertrand Fontaine, Vice President Research of
the Executive Board of the AP-HP. “We are counting on our
partnership with IntegraGen and the establishment of a pooled AP-HP
bioinformatics platform to strengthen our expertise in this area.
This partnership will also assist our biologists to better analyze
raw sequencing data, ultimately enabling them to better study the
correlation between phenotype and genetic variants."
The framework of the current agreement will also allow for the
development of additional ambitious research projects and
cooperative initiatives with outside research partners such as
academic universities and INSERM.
"IntegraGen is extremely proud to develop a sequencing
partnership for research projects and clinical research initiatives
which will be dedicated to all AP-HP,” said Bernard Courtieu,
IntegraGen’s CEO. “This is a major step in the growth of IntegraGen
and again demonstrates our ability to provide expert solutions
which meet the need of researchers and leads the way for the
clinical adoption of molecular and personalized medicine advances.
This strategic partnership demonstrates the recognition of the
quality results IntegraGen’s provides and the expertise we have
with sequencing platforms and advanced technologies, confirming our
leadership among global companies operating in this field."
ABOUT THE AP-HP
The Greater Paris University Hospitals, AP-HP is the Paris
area’s University Medical Center (UMC) and the leading UMC in
Europe. Its 39 hospitals treat over 8 million patients each year
either in consultation, for emergency care, for scheduled
hospitalizations, or for home hospitalization. The AP‐HP provides a
public health service for all, 24h a day as a necessity for
patients and with pride. The AP‐HP is the largest employer in the
Paris region with 95,000 people including doctors, researchers,
paramedicals, administrative staff and workers. For more
information about the AP‐HP visit www.aphp.fr.
ABOUT INTEGRAGEN
IntegraGen is a company specializing in deciphering the human
genome and producing relevant and easily interpretable data for
academic and private laboratories. IntegraGen’s oncology efforts
provide researchers and clinicians with sophisticated tools for
analysis and therapeutic individualization of treatment approaches
allowing them to tailor therapy to the genetic profiles of
patients. As of December 31, 2015, IntegraGen had 37 employees and
had generated revenue of €5.6 million in 2015. Based in Evry
Genopole, IntegraGen also has an U.S. office in Cambridge,
Massachusetts. IntegraGen is listed on Alternext of Euronext Paris
(ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).
For more information on IntegraGen visit www.integragen.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160629006241/en/
AP-HPAnne-Cécile Bard & Marine
LeroyService.presse@aphp.frTel : 01 40 27 37
22orINTEGRAGENBernard COURTIEUPresident and CEOorLaurence
RIOT LAMOTTEChief Financial Officercontact@integragen.comTel: +33
(0)1 60 91 09 00orNEWCAP.Investor and Media
RelationsEmmanuel HUYNHLouis-Victor DELOUVRIERNicolas
MERIGEAUintegragen@newcap.frTel: +33 (0)1 44 71 94 94
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024